Print Page | Contact Us | Sign In | Register
Upcoming Meeting Information
Share |

The Toxicology Forum is hosting a series of virtual sessions to facilitate dialogue and information exchange among presenters, panelists, and attendees.


  Register Here


Registration is required for these virtual sessions. Registration is all inclusive and attendees may attend any of the scheduled virtual sessions.

How will the virtual sessions function? Dialogue among presenters and attendees is a pillar of Toxicology Forum Meetings. In these virtual sessions, attendees will be able to contribute to the live discussion(s), ask questions, share their views, and participate in live polling and chat throughout the session.

Your voice and viewpoints drive the dialogue and we look forward to your continued contributions!


Upcoming Virtual Sessions


Few other areas of toxicology have such broad exposure and daily influence on public health across the entire population. Furthermore, frequently changing consumer preferences and regional variations in consumption patterns make exposure assessments more challenging. Consumers are highly vocal and emotionally attached to their food and quite rightly hold companies accountable for the safety of the foods they manufacture and the methods they use to assure this safety. While other industry sectors, such as industrial hygiene and cosmetics, are successfully embracing new scientific approaches and moving away from animal testing, safety assessments of novel food ingredients often continue to be based on data from  animal tests as recommended or required by regulatory agencies such as that in the FDA Red Book. The use of animal testing, whether required by regulations or not, can negatively influence the perception of a company and the food it produces and it is essential that animal testing is only used as a last resort when no other scientifically valid approaches are available. The complexities and uniqueness of food toxicology require the discussion around non-animal techniques to be specific to this industry. Never-the-less, food toxicologists can learn from other industry sectors leading the way and adapt to the changing landscape of our science. This session will examine non-animal techniques currently used in the evaluation of food ingredient safety and emerging techniques that may soon be more broadly accessible to the food industry. The session will also explore mechanisms to manage and evaluate these new data in the current regulatory environment, and stimulate discussion between different toxicology disciplines in order to identify key areas and actions that could be taken within the food industry to lead to more efficient adoption of non-animal approaches to safety assessment.

Presentation Schedule:

The Unique Nature of Food Ingredient Safety and Exposure Assessment: An Introduction
Paul Hanlon, Abbott Nutrition

Food-Relevant Regulations and Their Influence on Toxicology Methods
Candace Doepker, ToxStrategies Inc.

Case Studies on the Application of Alternative Methods to the Assessment of Food Substances
Sara Levorato, Unilever

Experience from Other Industries and Potential Relevance to Food Toxicology
Nadira DeAbrew, Procter & Gamble Company

Moderated Panel Discussion
Additional Panelists: Dennis Keefe, US FDA/CFSAN; and Paul Hepburn, Unilever
Moderator: Steve Hermansky, ConAgra

Linear low-dose extrapolation used in cancer risk assessment is based on the LNT. With the emerging understanding of the biology of cancer, a threshold-based approach for developing toxicity reference values could be used; an examples includes the 2005 Science Issue Paper: Mode of Carcinogenic Action for Cacodylic Acid V (Dimethylarsinic Acid, DMA) and Recommendations for Dose Response Extrapolation. Specifically, the use of LNT should be based on supporting best available biological evidence.

In the 21st century, experimental evidence for thresholds exists for some genotoxic agents and other chemicals associated with cancer. Biomonitoring has elevated the role of exposure science, and the new assessment methods (NAMs) provide an abundance of biological data. 

The purpose of this session is to advance the discussion of the role of this new knowledge in cancer risk assessment. 

Presentation Schedule:

The LNT Model of Radiation Effects: Origin and Inertia
Brant Ulsh, M.H. Chew & Assoc.

DNA Adducts and Mutagenicity, and Low-Dose Dose-Response
Lynn H Pottenger, LHP TOX CONSULT, LLC

Regulatory History and Current Agency Perspective on LNT
Anna Lowit, US EPA/OPP

Assessing Health Risks at Low Levels of Exposure—Historical and Future Perspectives
Daniel Krewski, University of Ottawa

Moderated Panel Discussion
Moderators: Ted Simon, Ted Simon LLC; and Edward Ohanian, US EPA

New approach methodologies (NAMs) offer great promise to improve human health risk assessment by centering on human biology, reducing the need to extrapolate from animal-based toxicity testing results. As NAMs are being accepted into health authority and regulatory decision-making as screening and prioritization tools, there is also interest in leveraging NAMs for quantitative risk assessment purposes. One of the acknowledged limitations of NAMs is their current inability to wholly reflect the complexity of biology, such as the impact of compensatory mechanisms. This session will address ongoing work in this area using systems-based approaches to identify adverse outcomes derived from NAMs. Two presentations from government and industry will discuss the concept of toxicological tipping points between adaptive and adverse responses, and comprehensive cellular stress panels integrated with probabilistic models and toxicokinetic considerations. Based on these advanced approaches it could be argued that NAMs deserve a more prominent role in risk assessment beyond their current accepted uses as screening and prioritization tools, provided exposure can also be effectively incorporated. These presentations will be complemented with another conversation on how health authorities are integrating NAMs into their decisions of potential endocrine disruption. A potential framework of how this Next Generation Risk Assessment could be achieved will also be shared and discussed. This multi-sector approach to better understanding the utility and opportunities of NAMs in risk assessment will support a risk-based approach to regulatory decision while still leveraging the cutting-edge technologies afforded by these advancements.

Presentation Schedule

Can We Identify Tipping Points between Adaptive and Adverse Perturbations from In Vitro Data?
Imran Shah, US EPA

Implementation of NAMs in a Next Generation Risk Assessment
Maria Baltazar, Unilever

Integration of NAM Data to Identify Chemicals with Endocrine Disruptor Properties under ECHA/EFSA Guidance 
Susan Borghoff, ToxStrategies Inc.

Moderated Panel Discussion
Additional Panelists:
Suzanne Fitzpatrick, US FDA/CFSAN
William Irwin, US EPA

Moderators: Phillip Wages, PepsiCo; Nicole Kleinstreuer, NIEHS/NICEATM


Please be sure to register in advance for the webinars. Registration is all inclusive for the three webinars.


Registration Fees:

Member: $100
Nonmember: $150

Registrants will receive an email with access information for each webinar in advance of the scheduled webinar date.


Important: If you have never joined an Event using Cisco WebEx, please take a minute and download the needed software in advance to ensure a seamless connection process.




Attendee Participation Details: The virtual sessions are held via Cisco WebEx. Attendees will be able to contribute verbally during the panel discussions and Q/A time after each presentation. Session chairs will call on individuals raising their hands to share their views and ask questions.

In addition to scientific presentations and the panel discussions, session organizers are working to integrate interactive polling and chat questions to help increase opportunities for dialogue and understanding among attendees. 


Questions: Please contact Kevin Merritt at The Toxicology Forum, either via email or phone {1.703.547.0876} with any questions or concerns about the virtual sessions.